#United States #Raleigh #Accord Healthcare #Hydrochlorothiazide #generic medications

Accord Healthcare Revives Hydrochlorothiazide Tablets

Accord Healthcare, Inc., a prominent player in the generic pharmaceutical industry, has recently announced the relaunch of Hydrochlorothiazide Tablets in three different strengths: 12.5 mg, 25 mg, and 50 mg. This move underscores the company's ongoing commitment to furnish accessible and affordable treatment options for patients battling various health conditions, particularly those relating to edema and hypertension.

Hydrochlorothiazide, a thiazide diuretic, is primarily used to treat high blood pressure and fluid retention caused by health issues like congestive heart failure, liver cirrhosis, and certain kidney disorders. Its efficacy as a supportive medication in conjunction with other therapeutic agents makes it an essential component in managing severe hypertension and related conditions. Nuvan Dassanaike, Senior Vice President of Digital Marketing Operations at Accord Healthcare, emphasized that this relaunch reaffirms their resolve to provide ongoing access to vital medications, especially for healthcare providers and patients relying on established treatment pathways.

Understanding Hydrochlorothiazide

Hydrochlorothiazide has been pivotal in medical treatments for several years, with its effectiveness being well-documented in comprehensive clinical studies. It helps manage hypertension by promoting the excretion of sodium and water through urine, ultimately leading to decreased blood pressure levels. Additionally, it alleviates edema in patients suffering from kidney, liver, or heart conditions.

While Hydrochlorothiazide is beneficial for many, it is crucial for users to be aware of potential contraindications and side effects. This medication should not be administered to individuals experiencing anuria (failure of the kidneys to produce urine) or those who exhibit hypersensitivity to hydrochlorothiazide or similar sulfonamide drugs.

Important Safety Information

Hydrochlorothiazide can present serious side effects, which may include:

• - Acute transient myopia and acute angle-closure glaucoma, often characterized by sudden vision changes or eye pain, necessitating immediate discontinuation of the drug.
• - Severe fluid and electrolyte imbalances, resulting in symptoms like weakness, confusion, dizziness, and gastrointestinal issues.
• - Potential exacerbation of pre-existing kidney or liver complications that could provoke dangerous conditions like azotemia or hepatic coma.
• - Risk of severe hypersensitivity reactions, which can manifest as anaphylaxis or respiratory distress.

Commonly Reported Side Effects

Users of Hydrochlorothiazide may also experience non-severe but notable side effects, including:

• - Dizziness and hypotension
• - Gastrointestinal discomfort, such as nausea or diarrhea
• - Blurred vision and headaches
• - Symptoms of fluid imbalance, which can pose further health risks if not closely monitored.

Regulatory Considerations

Hydrochlorothiazide is also prescribed with caution for pregnant women due to the risks associated with its use during pregnancy. It should only be used if deemed necessary, as it can cross the placental barrier and affect fetal health. Women who are nursing should consult healthcare providers regarding the continuation of this medication while breastfeeding.

Accord Healthcare's Mission

Accord Healthcare, a subsidiary of Intas Pharmaceuticals, aims to improve lives through access to medicines and innovative healthcare solutions. Leveraging advanced manufacturing technology coupled with in-house research, the company produces essential and affordable medications tailored to meet patient needs effectively. Further information about the Hydrochlorothiazide Tablets and other offerings can be found on the Accord Healthcare website.

In conclusion, Accord Healthcare’s revival of Hydrochlorothiazide Tablets not only enhances patient access to critically needed medicines but also reinforces the company's dedication to public health and therapeutic excellence in the pharmaceutical landscape.